The Molecular Weight of Tirzepatide: What It Tells You About the Medicine

What the 4,813-dalton figure actually means

Molecular weight is measured in daltons (Da) or, at this scale, kilodaltons (kDa). Tirzepatide sits at roughly 4.8 kDa. For context, a small-molecule medicine such as aspirin has a molecular weight of around 180 Da, barely a twentieth the size. That difference is not academic. Small molecules dissolve in water, pass through the gut wall, and reach the bloodstream in tablet form. Larger peptides like tirzepatide break down in the digestive tract before they can be absorbed, which is why the medicine cannot currently be taken as an ordinary tablet.

The 39-amino-acid backbone of tirzepatide is itself responsible for most of that molecular weight, and you can explore the full breakdown of atoms and bonds on our tirzepatide molecular formula page. The addition of a C20 fatty-acid side chain (attached via a linker) adds further mass and is the structural feature responsible for binding to albumin in the bloodstream. That albumin binding is precisely why tirzepatide stays active for roughly five days after a single injection, making a weekly dose schedule clinically practical. You can read more about how those structural features connect to the medicine's mechanism on our tirzepatide molecular structure page.

One practical note worth making: the prescribing information and the BNF entry for tirzepatide describe the medicine by its sequence and pharmacological class rather than by its molecular weight. Molecular weight is a chemistry reference, used in pharmaceutical development and academic papers rather than in day-to-day clinical notes. It does not affect which dose you start on or how the medicine behaves in your body, those are set by the product licence and confirmed in clinical trials.

How molecular size connects to tirzepatide's dual-agonist design

What distinguishes tirzepatide structurally from semaglutide and other GLP-1 medicines is that it was engineered to activate two receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. Achieving dual agonism in a single molecule required a sequence that could fold into two distinct binding conformations, which contributed to the relatively high molecular weight compared with earlier single-agonist peptides.

This dual-receptor activity is why tirzepatide is often described as a different class of medicine from earlier GLP-1 agents. It is the only dual GIP and GLP-1 receptor agonist licensed in the UK for weight management. The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% at the 15 mg dose over 72 weeks, results that reflect the added effect of GIP receptor activation on top of GLP-1 signalling, and our page on tirzepatide and weight gain explains what happens to those results if treatment is stopped or interrupted. More on the real-world implications of that evidence is covered on the tirzepatide and weight loss page.

The molecular complexity also means tirzepatide must be manufactured as a biological analogue rather than by simple chemical synthesis, a process that affects both cost and the need for a cold-chain supply. Mounjaro pens are stored refrigerated, and the storage window at room temperature is set out in the patient information leaflet; it is worth spending a minute checking that leaflet, or our frequently asked questions, if you are unsure whether a pen that has been left out is still suitable for use.

Molecular weight and why injectable delivery is the only licensed route for Mounjaro

The question of why tirzepatide cannot simply be taken as a tablet comes down, in large part, to its molecular weight. Peptides above roughly 1–2 kDa are generally too large to cross the intestinal epithelium in meaningful quantities without a specialised carrier. Tirzepatide at 4.8 kDa sits well above that threshold, which is why it is formulated as a subcutaneous injection delivered via the Mounjaro KwikPen.

This is a meaningful practical difference from the newer oral semaglutide formulation, which uses a fatty-acid absorption enhancer (SNAC) to overcome similar gut-wall barriers, though semaglutide's molecular weight is also substantial, at around 4.1 kDa. The tirzepatide molecule page goes into the structural comparison in more detail if you want to understand how the two compounds differ at a chemical level.

For people weighing up treatment options, the licensed dose strengths of tirzepatide in the UK run from 2.5 mg up to 15 mg; titration is supervised by a prescriber and paced to what your system tolerates. The molecular weight itself plays no part in that decision. What matters clinically (eligibility, medical history, other medicines you take) is assessed during a formal consultation. The overview of tirzepatide page sets out the eligibility criteria as they stand in the UK, and you can explore all licensed weight-loss options on our weight-loss treatments page.

When molecular chemistry becomes practically relevant: interactions and eligibility

There are a small number of situations where tirzepatide's peptide chemistry becomes directly relevant to patients rather than purely academic. Because it slows gastric emptying, tirzepatide can affect the absorption timing of other oral medicines taken alongside it, including oral contraceptives. The NHS advises that women using the pill alongside tirzepatide should add a non-oral form of contraception for the first four weeks of treatment and for four weeks after each dose increase, because the slowed gut transit can reduce pill absorption. This is a consequence of the medicine's pharmacodynamics rather than its molecular weight per se, but it stems from the same structural features that enable its mechanism of action.

Tirzepatide's peptide structure also means it is broken down by normal protein metabolism rather than by the liver enzymes (CYP450 system) that process many small-molecule drugs. This limits the number of serious drug-to-drug interactions compared with some other medicines, though your prescriber will still review your full medication list before approving treatment.

If you are considering Mounjaro and want to understand whether it fits your situation, the right starting point is a consultation with a qualified prescriber. Our clinical team (introduced on the clinical team profile page) reviews every application personally. You can also contact us if you have a question that does not fit a standard form. When you are ready, checking your eligibility takes only a few minutes and is free.